Lamivudine Aurovitas (Lamivudine)

Lamivudine is a nucleoside analogue that is phosphorylated inside cells to its active triphosphate form. This metabolite competes with natural nucleotides for incorporation by HIV reverse transcriptase and hepatitis B polymerase, causing premature termination of the viral DNA chain and thereby blocking viral replication.

The prescribing clinician determines the appropriate dose based on the patient’s specific condition, weight, renal function and whether it is used alone or in combination with other antivirals. Dosage may differ between HIV infection, chronic hepatitis B and prophylactic use, and adjustments are made according to clinical guidelines.

Safety data for lamivudine during pregnancy are limited, and the drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding decisions should follow local guidelines, as lamivudine is excreted in breast milk in small amounts.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Lamivudine Aurovitas. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class, similar to drugs such as tenofovir and emtricitabine. Compared with tenofovir, lamivudine generally has a lower risk of renal toxicity but may be less potent in some HIV regimens. Choice of agent depends on resistance patterns, patient comorbidities and treatment guidelines.

Lamivudine tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Lamivudine is administered orally as a tablet. It can be taken with or without food, and the tablet should be swallowed whole with water. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the regimen without medical advice.

Serious adverse events include lactic acidosis, severe hepatotoxicity, pancreatitis and severe skin reactions such as Stevens‑Johnson syndrome. Patients should be instructed to seek immediate medical attention if they experience unexplained fatigue, abdominal pain, rapid breathing, jaundice, severe rash or any signs of hypersensitivity.

Lamivudine is contraindicated in individuals with known hypersensitivity to the drug or any of its components. It should also be avoided in patients with pre‑existing severe mitochondrial disorders, uncontrolled liver disease, or those who have experienced serious adverse reactions to other nucleoside analogues.